Future Science Group

In this interview, we spoke to John Chappell, Senior Global Scientific Support Manager at Gyros Protein Technologies (Uppsala, Sweden) about his experience working with the Gyrolab platform for oligonucleotide assays. John discusses the advantages of using Gyrolab for oligo quantification in biological fluids and shares his thoughts on the next steps for these assays.

In the fifth episode of The New Frontier podcast, we're joined by Paul Byrne, Senior Director of Genomics from ProtaGene (MA, USA). Paul describes his experience working with qPCR vs digital and digital droplet PCR assays and advises on their pros and cons, as well as when it's best to use each. We discuss how these assays can be optimized for cell and gene therapy targets and get

In this episode of The New Frontier podcast, we're joined by Daniel Schulz-Jander, Senior Director of Mass spectrometry Bioanalysis at QPS Netherlands (Groningen). Daniel explains how he uses immune-precipitation and immunoaffinity LC–MS techniques for his work relating to macromolecular pharmaceuticals like gene therapies, as well as their benefits and challenges. Daniel also co

Breaking down barriers for women in tech: an interview with Tina Marshall by Future Science Group

What disparities exist in cancer screening and how does this impact patient outcomes? Listen to our latest podcast episode with Kilan Ashad-Bishop (American Cancer Society) to find out about the intersection between science, health, and society.

AI-driven early disease detection: an interview with Jim Kean by Future Science Group

In this episode, we spoke to Senior Director Johanna Mora about her experience with immunogenicity testing for cell and gene therapies (CGTs) and how she prepared for the expansion of BMS's portfolio to include CGTs. We discuss the importance of having diverse teams with a broad range of experiences to solve complex problems, as well as the role of artificial intelligence in improv

In the first episode of this series, we spoke to Executive Director and Global Head of Regulatory Services Kimberley Buytaert-Hoefen about her experience with cell and gene therapy (CGT) approvals and the barriers to getting these important therapeutics to the patient. Kim advises early regulatory interaction and collaboration to improve the success rate of applications and emphasi

AI and the UK Biobank: an interview with Mahesh Pancholi

In our new podcast series, we're joined by a Bioanalysis author to review their publication's biggest challenges, wider implications and next steps. In the final episode of series one, we're joined by Hetal Sarvaiya and Yuting Wang from AbbVie (MA, USA), who talk about the challenges of having an international team working on their perspective article and the inspiration behind the